Anti-CTLA4 x Anti-PD1 Bispecific Antibody (IgG-IgG) (BSIG-146)

Anti-CTLA4 x Anti-PD1 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CTLA4 and anti-PD1 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can bind two factors simultaneously and enhance immune response. It is designed for the research of Tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CTLA4 & PD1

Type

IgG-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Tumors

Targets

Target 1

CTLA4

Gene ID

1493

UniProt ID

P16410

Alternative Names

CTLA4; cytotoxic T-lymphocyte-associated protein 4; CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3; cytotoxic T-lymphocyte protein 4; CD152 isoform; celiac disease 3; insulin-dependent diabetes mellitus 12; cytotoxic T-lymphocyte-associated serine esterase-4; cytotoxic T lymphocyte associated antigen 4 short spliced form; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4

Target 2

PD1

Gene ID

5133

UniProt ID

Q15116

Alternative Names

PDCD1; programmed cell death 1; PD1; PD-1; CD279; SLEB2; hPD-1; hPD-l; hSLE1; programmed cell death protein 1; protein PD-1; systemic lupus erythematosus susceptibility 2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CTLA4 x Anti-PD1 Bispecific Antibody (IgG-IgG) (BSIG-146). Click the button below to contact us or submit your feedback about this product.

Anti-CTLA4 x Anti-PD1 Bispecific Antibody (IgG-IgG) (CAT#: BSIG-146)

Specifications

Targets

Customer Reviews and Q&As